Institute of Medicine Reports (IOM) Reaction Paper
Institute of Medicine Reports (IOM) Reaction Paper
In the year 1970, the government set up the Institute of Medicine (IOM) to provide scientific advice on issues of health, medicine, and biomedical science. Formation of the institute was mainly for the purpose of incorporating scientific knowledge on biomedical science, health, and medicine. From that year, the Institute has issued several reports. Some of the reports that the institute has issued include Humans Are Prone to Error in 1999. The report has a description of national well-being challenges. This report has had a big influence on the opinion of the public on different issues. Other reports of the Institute address issues of healthcare education, quality of health, public health, diversity, nursing, and disparity. Reports provide different recommendations on various issues they address.
This essay presents findings of a report “Future Prospects to Control the Alzheimer’s Syndrome Neuroimaging Proposal” by the Institute of Medicine. The report touches on the subject of aging and health. This essay describes findings of the report, presents recommendations, my reaction to the report, and how findings presented in the report can be applied. Findings of the report include a revelation that 5.3 million citizens in the United States live with Alzheimer’s syndrome. The report also denotes that about 26.6 million people are victims of Alzheimer’s disease globally. It also reports that there is no cure for the disease despite an intensive research and investigations done on the topic. The study also identifies a gap between academic research and private development research. Report states that there is a need to strengthen the relationship between academia, the government, and private sector in regulating Alzheimer’s disease with the neuroimaging initiative. I agree with report’s premise and think that adoption of neuroimaging in regulating Alzheimer’s disease is a major revolution. The information in the report can be applied to increase the quality of healthcare for Alzheimer syndrome patients (Institute of Medicine, 2011).
The IOM position report I have chosen is Future Prospects to Control the Alzheimer’s Syndrome Neuroimaging Proposal. This report falls under the subject of aging health. The report came out in 2010 as one of IOM’s moves to create avenues for regulating Alzheimer’s disease. The report was a culmination of a consortium between corporations, charity organizations dealing with Alzheimer’s disease, and the government. It provides an understanding of Alzheimer’s disease and addresses the question of how to advance procedures for clinical trials for its treatment (Institute of Medicine, 2011).
The report finds that almost 5.3 million citizens in the United States live with Alzheimer’s syndrome. The report also denotes that about 26.6 million people are victims of Alzheimer’s disease globally. It also says that there is no therapy for the disease despite the extensive research and investigations made on the topic. The report discusses benefits and challenges of creating worldwide programs to investigate the development of central nervous system and how neurodegenerative diseases, such as Alzheimer, affect it (Institute of Medicine, 2011).
Basic findings of the report include an explanation of Alzheimer’s disease. The report illustrates that Alzheimer’s syndrome is a neurological condition that causes firm degeneration in intellectual capacity. Alzheimer’ disease is the most regular manifestation of dementia (ADRF 2013). In most cases, the disease affects older adults. Its major symptoms include loss of memory and dementia.
The disease advances from one stage to another and its impact is incurable. It affects patient’s body both mentally and physically. Alzheimer’s disease causes unease in patients and sometimes it may lead to depression. A patient can also turn vicious towards his or her family members and caregivers. Alzheimer’s disease cannot be easily identified. The diagnosis can only be made after an autopsy examination at the demise of the patient. The nature of this disorder has led to increased concern of scientists about it. Transformation of demography leading to increase of old population means that there should be more focus on research about syndromes like Alzheimer’s disease to aid innovative science aiming at prevention and treatment of Alzheimer’s syndrome. Modern medicine lacks cure for Alzheimer’s disease. However, the use of relaxing and rehabilitative effects in the initial phases of the syndrome can hold a patient as long as possible in his/her usual social environment. It can also reduce the time of stay in inpatient psychiatric facilities (Dash, 2005).
The study reports that there is a gap between academic research and product studies and development in the private sector. This gap inhibits the progress in finding appropriate therapies for addressing the challenge of Alzheimer’s syndrome. This led to the partnership that formed the Alzheimer’s disease neuroimaging initiative (ADNA). The report points out that a partnership between the private sector in neurosciences and academia can contribute to the search for the cure of Alzheimer’s disease. The report provides examples of public–private associations that address several neurological ailments such as deteriorating dementia-focused Competence Network (DDCN) of the German Federal Ministry of Education and Research and the Innovative Medicines Initiative (IMI) in European Union.
The report finds that Alzheimer’s disease neuroimaging initiative can be spread for adoption in other forms of Alzheimer other than dementia. However, it discourages adoption of North America model of ADNA in other regions because of regional incompatibilities. The report notes that two major factors can allow the progress of ADNA. They entail having advocates to campaign for the initiative both in education and public setting, and having an agreement among scholars on creating the initiative (Institute of Medicine, 2011).
The report records that ADNA can be successful in regulating assortment of fluid biomarkers and imaging in a multisite environment, investigating the association between biomarkers and their courses over time to comprehend causal pathophysiology of the change from normal psychological aging to Alzheimer’s disease. ADNA can also assist in facilitating the integration of biomarkers into clinical trials for MCI and Alzheimer’s disease, creating an informational database that scientists can use, and enhancing partnerships among sectors, academia, industry, governments, and regulatory organizations globally (Institute of Medicine, 2011).
The report provides recommendations and discusses lessons that can be learnt from the use of ADNA. It illustrates that clinical and neuropsychological results measures cannot differentiate between a symptomatic advantage and a disease-modifying factor of a therapeutic product (Institute of Medicine, 2011).
The report recommends the creation of a record of clinical, neuroimaging, fluid biomarker, neuropsychological, and genetic data to make documentation of the best markers for monitoring disease development and treatment response more efficient.
The report recommends that Alzheimer’s disease neuroimaging initiative may be an important model for other illnesses such as Parkinson’s disease and atherosclerosis. It states that there is a need to increase pre-symptomatic research in regulation of Alzheimer’s disease.
The report articulates for the collection of data from psychologically normal individuals as well as those with MCI and moderate Alzheimer’s disease. This can increase understanding of Alzheimer’s disease.
In my opinion, the report is informative and relevant for fighting Alzheimer’s disease in America. I find report’s presentation on the neuroimaging initiative as a litigation measure to regulate Alzheimer’s disease precise and applicable. The neuroimaging initiative presents opportunities for controlling Alzheimer’s disease that has become a menace in America (Institute of Medicine, 2011).
I think that partnerships between the government, charitable institutions dealing with Alzheimer’s disease, and private sector can improve regulation of the disease. I agree with the report that there is a need to conduct more research on the development of Alzheimer’s disease. Research should focus on the initial stages of Alzheimer’s disease where there is little information.
In my opinion, the progress in regulation of Alzheimer’s disease can be made if similar progress occurs in other neurodegenerative ailments. I feel that these syndromes are connected and should be studied together. In addition, I think that earlier diagnosis tests of Alzheimer’s disease and identification of diets and lifestyles of patients can provide insights on factors that cause Alzheimer’s disease.
Application of information in this report can lead to improvement of the quality of methods for regulating Alzheimer’s disease. The report informs on key elements of Alzheimer’s disease neuroimaging initiative and how its application can redress challenges of the syndrome. It also illustrates lessons that can be learnt from the initiative of developing treatment methods of the disease. Rapid factors of Alzheimer’s disease that can be captured with advanced imaging skills could be used for algorithmic simulation of pathophysiology of the disease. In addition, Alzheimer’s disease neuroimaging initiative enhances research and partnership on regulation of Alzheimer’s disease in the world (Institute of Medicine, 2011).
In conclusion, the Institute of Medical Reports plays an important role in integrating scientific data with issues of biomedical science, health, and medicine. The institute has been releasing different reports over time that continue to inform decisions in health and medicine. The report is an essential step to curbing Alzheimer’s syndrome that has become a common problems among old people in the world.
Alzheimer’s Disease Research Foundation. (2013). About Alzheimer’s disease. Retrieved 21 May 2013 from Alzheimer’s Disease Research Foundation: http://alzheimers-research.org/
Dash, P. (2005). American academy of neurology: Alzheimer’s disease. New York, NY: Demos Medical Publishing.
The Institute of Medicine (2011). Impending prospects to regulate Alzheimer’s syndrome, the neuroimaging initiative. Washington: The National Academies Press.